2019
DOI: 10.1016/j.mam.2019.06.002
|View full text |Cite
|
Sign up to set email alerts
|

Circulating biomarkers for early detection and clinical management of colorectal cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
184
0
5

Year Published

2019
2019
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 224 publications
(191 citation statements)
references
References 223 publications
2
184
0
5
Order By: Relevance
“…Colorectal cancer (CRC) is diagnosed the second most cancer in females and the third most form in males, which has been a major global public health problem [1]. The number of cases diagnosed is forecast to rise from 1800 million now to 3093 million by 2040 through the World Health Organization [2]. Although modern medicine has made great advances, CRC is still the third leading cause for cancerrelated mortality [3].…”
Section: Introductionmentioning
confidence: 99%
“…Colorectal cancer (CRC) is diagnosed the second most cancer in females and the third most form in males, which has been a major global public health problem [1]. The number of cases diagnosed is forecast to rise from 1800 million now to 3093 million by 2040 through the World Health Organization [2]. Although modern medicine has made great advances, CRC is still the third leading cause for cancerrelated mortality [3].…”
Section: Introductionmentioning
confidence: 99%
“…Since the first reports on CTCs, the enumeration and analysis of the cells have attracted increasing attention due to their crucial roles in the metastatic cascade and the progression of metastasis. At present, CTC detection, via a novel method termed “liquid biopsies,” is widely used in the clinical treatment of various malignant tumor types . Compared to traditional tissue biopsy of solid neoplasms, noninvasive liquid biopsies are considered to be superior, and enable clinicians to use blood samples of only a few milliliters from cancer patients to perform "real‐time" monitoring and analysis of the cancer, to obtain more information at an earlier stage .…”
Section: Introductionmentioning
confidence: 99%
“…Therefore, it is vital to detect these gene mutations in an individualized manner. We believe this strategy can support the establishment of reasonable treatment plan for each patient (11)(12)(13)(14).…”
Section: Discussionmentioning
confidence: 85%